- Supernus Pharmaceuticals to Announce First Quarter 2024 Financial Results and Host Conference Call on May 8, 2024
- Supernus Provides Regulatory Update for SPN-830
- Supernus to Participate in Two Upcoming Investor Conferences
- Supernus to Participate in the TD Cowen 44th Annual Healthcare Conference
- Supernus Announces Fourth Quarter and Full Year 2023 Financial Results
- Supernus Pharmaceuticals to Announce Fourth Quarter and Full Year 2023 Financial Results and Host Conference Call on February 27, 2024
- Supernus Wins Infringement and Validity Case on Trokendi XR® against Torrent
- Supernus Announces Third Quarter 2023 Financial Results
- Supernus to Participate in the Jefferies London Healthcare Conference
- Supernus Announces SPN-830 Apomorphine Infusion Device NDA Accepted for Review by FDA
More ▼
Key statistics
On Friday, Supernus Pharmaceuticals Inc (SUPN:NMQ) closed at 30.07, -21.06% below its 52-week high of 38.09, set on May 03, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 29.46 |
---|---|
High | 30.19 |
Low | 29.17 |
Bid | 29.27 |
Offer | 31.58 |
Previous close | 29.31 |
Average volume | 330.20k |
---|---|
Shares outstanding | 54.73m |
Free float | 51.93m |
P/E (TTM) | 1,156.21 |
Market cap | 1.60bn USD |
EPS (TTM) | -0.0152 USD |
Data delayed at least 15 minutes, as of Apr 26 2024 21:00 BST.
More ▼